Literature DB >> 10678955

Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys.

A F Egan1, M J Blackman, D C Kaslow.   

Abstract

Protection against a lethal challenge infection of Plasmodium falciparum was elicited in malaria-naive Aotus vociferans monkeys by vaccination with the C terminus 19-kDa protein of the major merozoite surface protein (MSP-1(19)) fused to tetanus toxoid universal T-cell epitopes P30 and P2. Three of four monkeys were protected against a 10(4)-parasite challenge. Four monkeys were challenged with 10(5) parasites; one self-cured the infection, two were protected against high parasitemia (<2%) but were treated for severe anemia (hematocrit of <25%), and the fourth was not protected. In this model system, anemia appears to be a manifestation of incomplete protection (prolonged low-level parasitemia). Enzyme-linked immunosorbent assay (ELISA) antibody titers correlated with protection. Antibodies from some protected monkeys inhibited secondary processing of MSP-1(42) to MSP-1(33) and MSP-1(19). To mimic the repeated reinfections seen in regions where malaria is endemic, a second malaria parasite challenge was administered 4 months later. All P30P2MSP-1(19)-vaccinated monkeys were protected; thus, a single challenge infection may underestimate vaccine efficacy. ELISA antibody titers correlated with protection against a second infection but had decreased compared to the first challenge. As most target populations for asexual blood-stage malaria vaccines will have been exposed to malaria parasites, a malaria parasite-exposed monkey was vaccinated with P30P2MSP-1(19). This monkey was completely protected, while a malaria parasite-naive P30P2MSP-1(19)-vaccinated monkey self-cured a low-grade parasitemia. Prior malaria parasite infection primed the production of anti-native MSP-1(19) antibodies, which were boosted by vaccination with recombinant P30P2MSP-1(19). Preliminary data suggest that immunogenicity studies of vaccines designed for malaria parasite-exposed populations should also be conducted in malaria parasite-exposed subjects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10678955      PMCID: PMC97296          DOI: 10.1128/IAI.68.3.1418-1427.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex.

Authors:  J S McBride; H G Heidrich
Journal:  Mol Biochem Parasitol       Date:  1987-02       Impact factor: 1.759

2.  Induction of protective immunity to monoclonal-antibody-defined Plasmodium falciparum antigens requires strong adjuvant in Aotus monkeys.

Authors:  W A Siddiqui; L Q Tam; S C Kan; K J Kramer; S E Case; K L Palmer; K M Yamaga; G S Hui
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

3.  Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen.

Authors:  J A Deans; A M Knight; W C Jean; A P Waters; S Cohen; G H Mitchell
Journal:  Parasite Immunol       Date:  1988-09       Impact factor: 2.280

4.  Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria.

Authors:  W A Siddiqui; L Q Tam; K J Kramer; G S Hui; S E Case; K M Yamaga; S P Chang; E B Chan; S C Kan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

5.  Major surface antigen gene of a human malaria parasite cloned and expressed in bacteria.

Authors:  R Hall; J E Hyde; M Goman; D L Simmons; I A Hope; M Mackay; J Scaife; B Merkli; R Richle; J Stocker
Journal:  Nature       Date:  1984 Sep 27-Oct 3       Impact factor: 49.962

6.  Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum.

Authors:  H M Etlinger; P Caspers; H Matile; H J Schoenfeld; D Stueber; B Takacs
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

7.  Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites.

Authors:  A A Holder; M J Lockyer; K G Odink; J S Sandhu; V Riveros-Moreno; S C Nicholls; Y Hillman; L S Davey; M L Tizard; R T Schwarz
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

8.  Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro.

Authors:  A F Egan; P Burghaus; P Druilhe; A A Holder; E M Riley
Journal:  Parasite Immunol       Date:  1999-03       Impact factor: 2.280

9.  Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains.

Authors:  M J Blackman; I T Ling; S C Nicholls; A A Holder
Journal:  Mol Biochem Parasitol       Date:  1991-11       Impact factor: 1.759

10.  A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies.

Authors:  M J Blackman; H G Heidrich; S Donachie; J S McBride; A A Holder
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

View more
  22 in total

1.  Reference strand conformational analysis (RSCA) is a valuable tool in identifying MHC-DRB sequences in three species of Aotus monkeys.

Authors:  Juan E Baquero; Santiago Miranda; Oscar Murillo; Heidy Mateus; Esperanza Trujillo; Carlos Suarez; Manuel E Patarroyo; Carlos Parra-López
Journal:  Immunogenetics       Date:  2006-05-30       Impact factor: 2.846

2.  A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum.

Authors:  Anthony W Stowers; Li-how Chen Lh; Yanling Zhang; Michael C Kennedy; Lanling Zou; Lynn Lambert; Timothy J Rice; David C Kaslow; Allan Saul; Carole A Long; Harry Meade; Louis H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.

Authors:  Suman Mazumdar; Paushali Mukherjee; Syed Shams Yazdani; S K Jain; Asif Mohmmed; Virander Singh Chauhan
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

4.  Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria.

Authors:  Anthony W Stowers; Michael C Kennedy; Brian P Keegan; Allan Saul; Carole A Long; Louis H Miller
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

5.  Detection of Plasmodium falciparum, P. vivax, P. ovale, and P. malariae merozoite surface protein 1-p19 antibodies in human malaria patients and experimentally infected nonhuman primates.

Authors:  A Scott Muerhoff; Larry G Birkenmeyer; Ruthie Coffey; Bruce J Dille; John W Barnwell; William E Collins; Joann S Sullivan; George J Dawson; Suresh M Desai
Journal:  Clin Vaccine Immunol       Date:  2010-08-11

6.  Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum.

Authors:  Ute Woehlbier; Christian Epp; Christian W Kauth; Rolf Lutz; Carole A Long; Boubacar Coulibaly; Bocar Kouyaté; Myriam Arevalo-Herrera; Sócrates Herrera; Hermann Bujard
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

7.  Evaluation of the naturally acquired antibody immune response to the Pv200L N-terminal fragment of Plasmodium vivax merozoite surface protein-1 in four areas of the Amazon Region of Brazil.

Authors:  Luciane M Storti-Melo; Wanessa C Souza-Neiras; Gustavo C Cassiano; Leonardo C Taveira; Antônio J Cordeiro; Vanja S C A Couto; Marinete M Póvoa; Maristela G Cunha; Diana M Echeverry; Andréa R B Rossit; Myriam Arévalo-Herrera; Sócrates Herrera; Ricardo L D Machado
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

Review 8.  Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Authors:  Kwang-Chul Kwon; Dheeraj Verma; Nameirakpam D Singh; Roland Herzog; Henry Daniell
Journal:  Adv Drug Deliv Rev       Date:  2012-10-23       Impact factor: 15.470

9.  Effect of GPI anchor moiety on the immunogenicity of DNA plasmids encoding the 19-kDa C-terminal portion of Plasmodium falciparum MSP-1.

Authors:  G Li; S H Basagoudanavar; D C Gowda
Journal:  Parasite Immunol       Date:  2008-04-14       Impact factor: 2.280

10.  Can prenatal malaria exposure produce an immune tolerant phenotype? A prospective birth cohort study in Kenya.

Authors:  Indu Malhotra; Arlene Dent; Peter Mungai; Alex Wamachi; John H Ouma; David L Narum; Eric Muchiri; Daniel J Tisch; Christopher L King
Journal:  PLoS Med       Date:  2009-07-28       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.